Phase I trial of edatrexate plus carboplatin in advanced solid tumors: Amelioration of dose-limiting mucositis by ice chip cryotherapy

Investigational New Drugs

Volumn 16, Issue 1, 1998, Pages 69-75

  Edelman, Martin J ^a,c   Gandara, David R ^a,c   Perez, Edith A ^b   Lau, Derrick ^a   Lauder, Ignacio ^c   Turrell, Corrine ^a   Uhrich, Margaret ^a   Meyers, Frederick ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Carboplatin; Cryotherapy; Edatrexate; Mucositis

Indexed keywords

CARBOPLATIN; EDATREXATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CRYOTHERAPY; DISEASE SEVERITY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

EID: 0031823628     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006026928733     Document Type: Article

References (26)

1. Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ: New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacological properties. Cancer Chemother Pharmacol 12:18-25, 1984
2. Schmid FA, Sirotnak FM, Otter GM, DeGraw JI: New folate analogs of the 10-deaza-aminopterin series. Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 69:551-552, 1985
3. Sirotnak FM, DeGraw JI, Schmid FA, Goutas LJ, Moccio DM: New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12:26-30, 1984
4. Canetta R, Goodlow J, Smaldone L, Bragman K, Rozencweig M: Pharmacologic characteristics of carboplatin: clinical experience. In: Bunn Jr PA, Canetta R, Ozols RF, Rozencweig M (eds) Carboplatin (JM-8). Current Perspective and Future Directions. Philadelphia: WB Saunders Company, pp 19-38, 1990
5. Chou TC, Tan QH, Sirotnak FM: Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 31:259-264, 1993
6. Perez EA, Hack FM, Webber L, Chou TC: Schedule dependent synergism of edatrexate and cisplatin combination in the A549 lung cancer cell line as assessed by median effect analysis. Cancer Chemother Pharmacol 33:245-250, 1993
7. Perez EA, Hack FM, Fletcher T, Chou TC: Modulation of intrinsic in vitro resistance to carboplatin by edatrexate. Oncol Res 34:331-334, 1994
8. Lee JS, Libshitz HI, Murphy WK, Jeffries D, Hong WK: Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage III B or IV non-small cell lung cancer. Invest New Drugs 8:299-304, 1990
9. Lee JS, Murphy WK, Shirinian MH, Pang A, Hong WK: Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy. Cancer Chemother Pharmacol 28:199-204, 1991
10. VandenBerg RA, Pritchard KI, Eisenhauer EA, Trudeau ME, Norris BD, Lopez P, Verma SS, Buckman RA, Muldal A: Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Trials Group Study. J Clin Oncol 11:1241-1244, 1993
11. Schornagel JH, Verweij J, de Mulder PHM, Cognetti F, Vermerken JB, Cappaelaere P, Armand JP, Wildiers J, Clavel M, Sahmoud T, Kirkpatrick A, Lefebvre JL: Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Center Cooperative Group Study. J Clin Oncol 13:1649-1655, 1995
12. Shum KY, Kris MG, Gralla RJ, Burke T, Marks LD, Heelan RT: Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 6:446-450, 1988
13. Kris MG, Kinahan JJ, Gralla RJ, Fanucchi MP, Wertheim MS, O'Connell JP, Marks LD, Williams L, Farag F, Young CW, Sirotnak FM: Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deaza-aminopterin in adult patients with advanced cancer. Cancer Res 48:5573-5579, 1988
14. Gandara DR, Ferez EA, Edelman MJ, Lau D, Lauder I, Turrell C, Meyers F: Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting toxicity mucositis by ice chip cryotherapy. Proc Am Soc Clin Oncol 14:468, 1995
15. Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, Sorensen JM, Gainey DK, Mailliard JA, Gusa NL, Finck GK, Johnson C, Goldberg RM: Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9:449-452, 1991
16. Hartley JM, Nicholson PW, Allen R, Lamond P, Harland SJ, Souhami RL: Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer. Cancer Chemother Pharmacol 31:328-332, 1993
17. Grant SC, Kris MG, Young CW, Sirotnak FM: Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest 11(1):36-45, 1993
18. Lee JS, Libshitz HI, Fosella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK: Edatrexate improves the antitumor effects of cyclophos-phamide and cisplatin against non-small cell lung cancer. Cancer 68:959-964, 1991
19. Grunberg SM, Spears CP, Natale R, Zaretsky S, Ashikaga T: Phase I evaluation of high-dose edatrexate (EDX) with leucovorin (LV) rescue. Proc Am Soc Clin Oncol 13:146, 1994
20. Fosella FV, Lee JS, Winn R, Wester M, Graham S, Holder LW, Goodwin JW, Dakhil SR, Hong WK: Edatrexae (E) + Ifosfamide (I) + cisplatin (P) with leucovorin (LV) and mesna (M) for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:371, 1995
21. Ferez EA, Whitall D, Hesketh PJ: Phase I trial of biweekly edatrexate in metastatic breast cancer. Proc Am Soc Clin Oncol 13:59, 1994
22. Sirotnak FM, Otter GM, Schmid FA: Markedly improved efficacy of edatrexatc compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors. Cancer Res 53(3):587-591, 1993
23. Jolivet J, Jansen G, Peters GJ, Pinard MF, Schornagel JH: Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate. Biochem Pharmacol 47(4):659-665, 1994
24. Calvert AH, Newell DR, Gumbrell LA, O' Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
25. Izquierdo MA, Sanchez A, Llort G, Moreno V, Rey M, Germa JR: Comparison of different methods for AUC dosing of carboplatin (cbdca). Proc Am Soc Clin Oncol 16:204a(#714), 1997
26. 2 in patients with advanced non-small cell lung cancer (nsclc): is there an impact of the reached area under the curve (auc) on response, survival and hematological toxicity? Proc Am Soc Clin Oncol 16:205a(#716), 1997